Business Wire

CITY-OF-TAMPERE

15.5.2019 14:11:10 CEST | Business Wire | Press release

Share
City of Tampere: an International Ideas Competition in a Magnificent Finnish Lakeside City

An international ideas competition started off on 15 May 2019 in Viinikanlahti, a highly exciting area close to Tampere city centre. Competitors get to design a housing area of over 3,000 residents on the shores of Lake Pyhäjärvi, as well as a leisure time environment for the locals and tourists. With a population of roughly 370,000, the sustainably growing Tampere is the largest inland city in the Nordic Countries and, together with the neighbouring municipalities, forms the second-largest urban area in Finland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190515005494/en/

The aim of the ideas competition, which is open to all, is to create a new and ecologically sustainable city district that boasts high-quality architecture and meets the needs of the 21st century. The competition task is exceptionally interesting: the unique Viinikanlahti area has the most beautiful lake views in the centre of Tampere, but also involves environmental challenges. The size of the competition area (land and water) is roughly 0.4 hectares. The wastewater treatment plant currently operating in the area will be moved elsewhere. After the competition, both a master plan and a local detailed plan will be prepared for the area. The environment will be cleaned and the new city district constructed in phases between 2024-2035.

The international ideas competition is organised mainly digitally, and is expected to attract plenty of participants from Finland and abroad. A total of 165,000–345,000 euros will be awarded in prizes in the two-phased competition, the winner of which will be selected in April 2020. The competition is organised by the City of Tampere in cooperation with the Finnish Association of Architects (SAFA) and the Association of Finnish Landscape Architects (MARK).

The economy of the City of Tampere focuses on services and high-technology. Innovative, digital, and sustainable smart city solutions are being created in the region together with companies, research institutions, municipalities, and residents. The population of Tampere is increasing by over 3,000 residents a year. New construction is constantly being implemented in the area, and new ecological and low-emission solutions are needed to enable the carbon-neutral and sustainable growth of the city in accordance with its strategy.

Competition website:

www.tampere.fi/viinikanlahti

Further information:

https://businesstampere.com/

https://visittampere.fi/en/

YouTube: @tampereenkaupunki

Contact:

Executive Director, Growth, Innovation and Competitiveness Services Teppo Rantanen +358 400235442 teppo.t.rantanen@tampere.fi Project Director Tero Tenhunen +358 505402860 tero.tenhunen@tampere.fi Project Development Manager Minna Seppänen +358 401509857 minna.seppanen@tampere.fi

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye